GSK (NYSE: GSK) executives record share plan purchases and 10,000 ADS sale

Rhea-AI Filing Summary

GSK plc reported several routine share dealings by senior leaders and a person closely associated with a leader. Multiple executives, including the President, Europe and the Chief Financial Officer, each acquired 10 or 12 ordinary shares at £21.7918 under the Company’s Share Reward Plan on 2026-02-10 via the London Stock Exchange.

The filing also notes that the Chief People Officer sold 10,000 American Depositary Shares at $59.1802 per ADS on 2026-02-09 on the New York Stock Exchange. All transactions are classified as initial notifications and involve GSK ordinary shares or ADS representing the company.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	5 (partnership shares)
			£21.7918	5 (matching shares)
		d)	Aggregated information
Aggregated volume Price	10 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7918	6 (partnership shares)
			£21.7918	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £21.7918
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Sale of 10,000 ADS
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.1802	10,000
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 11, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider share transactions did GSK (GSK) disclose in this report?

GSK disclosed multiple insider share transactions involving senior leaders. Several executives acquired small amounts of ordinary shares under the Share Reward Plan, while the Chief People Officer sold 10,000 American Depositary Shares on the New York Stock Exchange at a stated price per ADS.

Which GSK (GSK) executives acquired shares under the Share Reward Plan?

Lynn Baxter, Julie Brown, James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte and PCA Neil Falkingham acquired shares. Each received 10 or 12 ordinary shares at £21.7918 per share through partnership and matching shares on the London Stock Exchange.

What details were provided about the GSK (GSK) Chief People Officer’s ADS sale?

Chief People Officer Diana Conrad sold 10,000 American Depositary Shares. The sale occurred on 2026-02-09 at a price of $59.1802 per ADS, executed on the New York Stock Exchange, and was reported as a single aggregated transaction in the filing.

On what dates and exchanges did the GSK (GSK) insider trades occur?

The ordinary share acquisitions took place on 2026-02-10 on the London Stock Exchange. The 10,000 ADS sale by the Chief People Officer occurred earlier, on 2026-02-09, on the New York Stock Exchange, with each transaction clearly tied to its trading venue.

What type of securities were involved in the GSK (GSK) insider dealings?

The dealings involved GSK ordinary shares and American Depositary Shares. Executives acquired ordinary shares of 31¼ pence each under the Share Reward Plan, while the Chief People Officer’s transaction related to American Depositary Shares listed and traded on the New York Stock Exchange.

How were prices and volumes structured for GSK (GSK) Share Reward Plan acquisitions?

Share Reward Plan acquisitions used a single reference price with split volumes. For most executives, 6 partnership shares and 6 matching shares were acquired at £21.7918, totaling 12 ordinary shares; one executive received 5 partnership and 5 matching shares, totaling 10 shares.